Immix Biopharma Stock Performance
| IMMX Stock | USD 1.72 0.07 3.91% |
The company retains a Market Volatility (i.e., Beta) of 1.35, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immix Biopharma will likely underperform. At this point, Immix Biopharma has a negative expected return of -0.25%. Please make sure to check out Immix Biopharma's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immix Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immix Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Immix CAR-T Therapy IND Cleared by FDA, Stock Down - MSN | 09/23/2024 |
2 | Acquisition by Morris Gabriel S of 4500 shares of Immix Biopharma at 2.2315 subject to Rule 16b-3 | 09/27/2024 |
3 | Acquisition by Buchan Jane of 1332 shares of Immix Biopharma subject to Rule 16b-3 | 10/18/2024 |
4 | Immix Biopharma Posts Quarterly Earnings Results, Misses Expectations By 0.08 EPS | 11/14/2024 |
| Begin Period Cash Flow | 13.4 M |
Immix |
Immix Biopharma Relative Risk vs. Return Landscape
If you would invest 222.00 in Immix Biopharma on August 28, 2024 and sell it today you would lose (50.00) from holding Immix Biopharma or give up 22.52% of portfolio value over 90 days. Immix Biopharma is currently does not generate positive expected returns and assumes 5.6613% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Immix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immix Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immix Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immix Biopharma, and traders can use it to determine the average amount a Immix Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0445
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMMX |
Estimated Market Risk
| 5.66 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immix Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immix Biopharma by adding Immix Biopharma to a well-diversified portfolio.
Immix Biopharma Fundamentals Growth
Immix Stock prices reflect investors' perceptions of the future prospects and financial health of Immix Biopharma, and Immix Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immix Stock performance.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 30.64 M | ||||
| Shares Outstanding | 27.51 M | ||||
| Price To Book | 2.81 X | ||||
| EBITDA | (16.14 M) | ||||
| Net Income | (15.6 M) | ||||
| Cash And Equivalents | 18.4 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 3.72 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 19.53 X | ||||
| Book Value Per Share | 0.82 X | ||||
| Cash Flow From Operations | (11.37 M) | ||||
| Earnings Per Share | (0.84) X | ||||
| Market Capitalization | 49.24 M | ||||
| Total Asset | 19.93 M | ||||
| Retained Earnings | (53.41 M) | ||||
| Working Capital | 16.07 M | ||||
About Immix Biopharma Performance
Evaluating Immix Biopharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immix Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immix Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (1.00) | (0.95) | |
| Return On Assets | (0.77) | (0.81) | |
| Return On Equity | (0.94) | (0.99) |
Things to note about Immix Biopharma performance evaluation
Checking the ongoing alerts about Immix Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immix Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immix Biopharma generated a negative expected return over the last 90 days | |
| Immix Biopharma has high historical volatility and very poor performance | |
| Immix Biopharma may become a speculative penny stock | |
| Immix Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (15.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immix Biopharma currently holds about 18.4 M in cash with (11.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Immix Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Immix Biopharma Posts Quarterly Earnings Results, Misses Expectations By 0.08 EPS |
- Analyzing Immix Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immix Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Immix Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immix Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immix Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immix Biopharma's stock. These opinions can provide insight into Immix Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.